The effect of Liraglutide treatment on postprandial chylomicron and VLDL kinetics, liver fat and de novo lipogenesis. A single-center randomized controlled study.

Trial Profile

The effect of Liraglutide treatment on postprandial chylomicron and VLDL kinetics, liver fat and de novo lipogenesis. A single-center randomized controlled study.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Jan 2018

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Pharmacokinetics; Therapeutic Use
  • Acronyms LIRA
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 24 Jan 2018 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.
    • 24 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top